JP2021112211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021112211A5 JP2021112211A5 JP2021079698A JP2021079698A JP2021112211A5 JP 2021112211 A5 JP2021112211 A5 JP 2021112211A5 JP 2021079698 A JP2021079698 A JP 2021079698A JP 2021079698 A JP2021079698 A JP 2021079698A JP 2021112211 A5 JP2021112211 A5 JP 2021112211A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- composition according
- grna
- multicellular organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020005004 Guide RNA Proteins 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 3
- 230000004807 localization Effects 0.000 claims 3
- 108091033409 CRISPR Proteins 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021141109A JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181162P | 2015-06-17 | 2015-06-17 | |
| US62/181,162 | 2015-06-17 | ||
| JP2018517674A JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Division JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021141109A Division JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021112211A JP2021112211A (ja) | 2021-08-05 |
| JP2021112211A5 true JP2021112211A5 (enExample) | 2021-10-14 |
| JP7170090B2 JP7170090B2 (ja) | 2022-11-11 |
Family
ID=56292934
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Ceased JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021079698A Active JP7170090B2 (ja) | 2015-06-17 | 2021-05-10 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
| JP2021141109A Withdrawn JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517674A Ceased JP2018521689A (ja) | 2015-06-17 | 2016-06-16 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021141109A Withdrawn JP2021182942A (ja) | 2015-06-17 | 2021-08-31 | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11473082B2 (enExample) |
| EP (2) | EP3929286A1 (enExample) |
| JP (3) | JP2018521689A (enExample) |
| KR (1) | KR102637402B1 (enExample) |
| CN (1) | CN108026519A (enExample) |
| AU (2) | AU2016278226B2 (enExample) |
| CA (1) | CA2989827C (enExample) |
| DK (1) | DK3310909T3 (enExample) |
| ES (1) | ES2886599T3 (enExample) |
| PT (1) | PT3310909T (enExample) |
| WO (1) | WO2016205554A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2920319B1 (en) | 2012-11-16 | 2020-02-19 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
| KR102455807B1 (ko) | 2014-10-01 | 2022-10-18 | 더 제너럴 하스피탈 코포레이션 | 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법 |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| WO2018064681A1 (en) * | 2016-09-30 | 2018-04-05 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| WO2018169948A1 (en) | 2017-03-13 | 2018-09-20 | Poseida Therapeutics, Inc. | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| KR102655021B1 (ko) | 2017-07-11 | 2024-04-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용 |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| WO2019126578A1 (en) * | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| CN112543808A (zh) | 2018-06-21 | 2021-03-23 | 比莫根生物科技公司 | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 |
| CN110938658B (zh) * | 2018-09-21 | 2023-02-07 | 中国科学院分子细胞科学卓越创新中心 | 一种抗体进化方法及其应用 |
| WO2020077360A1 (en) | 2018-10-12 | 2020-04-16 | Poseida Therapeutics, Inc. | Hematopoietic stem cell compositions, methods of making and method of use |
| AU2019401282A1 (en) | 2018-12-20 | 2021-07-15 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| WO2020160481A1 (en) * | 2019-02-01 | 2020-08-06 | The General Hospital Corporation | Targetable 3'-overhang nuclease fusion proteins |
| US20220204569A1 (en) * | 2019-04-09 | 2022-06-30 | Japan Science And Technology Agency | Nucleic acid-binding protein |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| CN114761424B (zh) | 2019-09-05 | 2025-09-19 | 波赛达治疗公司 | 同种异体细胞组合物和使用方法 |
| JP7743407B2 (ja) | 2019-12-20 | 2025-09-24 | ポセイダ セラピューティクス，インコーポレイティド | 抗Ｍｕｃ１組成物及び使用方法 |
| US20230121433A1 (en) | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| WO2022087148A1 (en) | 2020-10-21 | 2022-04-28 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| US20230399660A1 (en) * | 2020-10-23 | 2023-12-14 | Altius Institute For Biomedical Sciences | Cell Permeable Proteins for Genome Engineering |
| CN112750498B (zh) * | 2020-12-30 | 2022-06-24 | 同济大学 | 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法 |
| EP4298205A1 (en) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
| CA3208993A1 (en) | 2021-02-23 | 2022-09-01 | Joshua RYCHAK | Compositions and methods for delivery of nucleic acids |
| US20240424097A1 (en) | 2021-09-09 | 2024-12-26 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| CA3233506A1 (en) | 2021-10-04 | 2023-04-13 | Joseph S. LUCAS | Transposon compositions and methods of use thereof |
| US20250099383A1 (en) | 2022-01-21 | 2025-03-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| EP4482967A1 (en) * | 2022-02-23 | 2025-01-01 | Poseida Therapeutics, Inc. | Genetically modified cells and methods of use thereof |
| WO2023209649A1 (en) * | 2022-04-29 | 2023-11-02 | Seqirus, Inc. | Method of dna linearization |
| WO2024007010A2 (en) * | 2022-06-30 | 2024-01-04 | Demeetra Agbio, Inc. | Gene editing compositions and methods of use thereof |
| WO2024084025A1 (en) | 2022-10-21 | 2024-04-25 | Keygene N.V. | Rna transfection in plant cells with modified rna |
| CN120225666A (zh) | 2022-11-21 | 2025-06-27 | 艾欧凡斯生物治疗公司 | 用于评估基因编辑的t细胞的增殖效力的方法 |
| KR20250122544A (ko) | 2022-11-21 | 2025-08-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024121354A1 (en) | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| JP2026503551A (ja) | 2023-01-20 | 2026-01-29 | ポセイダ セラピューティクス，インコーポレイティド | リピドイド化合物ならびに関連する組成物および使用 |
| EP4652153A1 (en) | 2023-01-20 | 2025-11-26 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| KR20250166122A (ko) | 2023-02-21 | 2025-11-27 | 포세이다 테라퓨틱스, 인크. | 게놈 편집을 위한 조성물 및 방법 |
| AU2024224169A1 (en) | 2023-02-21 | 2025-08-21 | Poseida Therapeutics, Inc. | Compositions and methods for genome editing |
| WO2024209000A1 (en) | 2023-04-04 | 2024-10-10 | Keygene N.V. | Linkers for duplex sequencing |
| EP4713454A1 (en) | 2023-05-17 | 2026-03-25 | Poseida Therapeutics, Inc. | Compositions targeting hbg1 and hbg2 and methods of use thereof |
| WO2025049925A2 (en) | 2023-09-01 | 2025-03-06 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025096980A1 (en) | 2023-11-02 | 2025-05-08 | Poseida Therapeutics, Inc. | Compositions targeting klkb1 and methods of use thereof |
| WO2025160432A1 (en) | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
| WO2025171237A1 (en) | 2024-02-08 | 2025-08-14 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025221789A1 (en) | 2024-04-16 | 2025-10-23 | Poseida Therapeutics, Inc. | Compositions and methods for use in car/tcr cell therapies |
| WO2026030277A1 (en) | 2024-08-01 | 2026-02-05 | Amgen Inc. | Method for reducing protease activities |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| TW261517B (enExample) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
| JP4216350B2 (ja) | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えｄｎａウイルスベクター |
| US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
| US5869040A (en) | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
| US5928914A (en) | 1996-06-14 | 1999-07-27 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Methods and compositions for transforming cells |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| CA2246005A1 (en) | 1998-10-01 | 2000-04-01 | Hsc Research And Development Limited Partnership | Hybrid genes for gene therapy in erythroid cells |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| WO2000071702A1 (en) | 1999-05-25 | 2000-11-30 | Panorama Research, Inc. | Interaction-activated proteins |
| DE60126483T2 (de) | 2000-04-28 | 2007-12-06 | Sangamo BioSciences, Inc., Richmond | Gezielte Modifikation der Chromatinstruktur |
| DK1353941T3 (da) | 2001-01-22 | 2013-06-17 | Sangamo Biosciences Inc | Modificerede zinkfingerbindingsproteiner |
| AU2002304163C1 (en) * | 2001-06-05 | 2009-01-08 | Oriental Yeast Co., Ltd. | Polypeptide unstabilizing protein in cells under aerobic conditions and DNA encoding the same |
| US20030138850A1 (en) | 2001-10-18 | 2003-07-24 | Ekkehard Mossner | Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| US7790379B2 (en) | 2005-05-19 | 2010-09-07 | Universite De Geneve | Mapping of proteins along chromatin by chromatin cleavage |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| JP2007159512A (ja) | 2005-12-15 | 2007-06-28 | Institute Of Physical & Chemical Research | Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法 |
| WO2007122511A2 (en) | 2006-04-21 | 2007-11-01 | Mab-Factory Gmbh | Antibody-rnase-conjugate |
| EP2155868A2 (en) | 2007-04-19 | 2010-02-24 | Codon Devices, Inc | Engineered nucleases and their uses for nucleic acid assembly |
| EP2188372A4 (en) | 2007-09-17 | 2011-03-02 | Affomix Corp | INCREASING THE SPECIFICITY OF SCFV SCREENING USING TWO BAIT REPORTERS |
| CA2753287A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| KR20110139216A (ko) | 2009-03-11 | 2011-12-28 | 와이어쓰 엘엘씨 | 소형 모듈형 면역약제 단백질의 정제 방법 |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| WO2012093833A2 (en) * | 2011-01-03 | 2012-07-12 | Toolgen Incorporation | Genome engineering via designed tal effector nucleases |
| CN103328507B (zh) | 2011-01-06 | 2016-09-07 | 康普里斯股份有限公司 | Alphabody文库及其产生方法 |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2522726A1 (en) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinc finger nucleases for p53 editing |
| US20140201858A1 (en) | 2011-05-17 | 2014-07-17 | Transposagen Biopharmaceuticals, Inc | Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms |
| EP2718446A2 (en) | 2011-06-07 | 2014-04-16 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| DK3434775T3 (da) | 2011-06-07 | 2020-04-06 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf |
| IN2014MN00974A (enExample) | 2011-12-16 | 2015-04-24 | Targetgene Biotechnologies Ltd | |
| WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| PL4289948T3 (pl) * | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| US9181535B2 (en) * | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| DK2911687T3 (da) | 2012-10-26 | 2019-05-13 | Univ Brussel Vrije | Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf |
| EP2920319B1 (en) | 2012-11-16 | 2020-02-19 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
| CN105142669B (zh) | 2012-12-06 | 2018-07-03 | 西格马-奥尔德里奇有限责任公司 | 基于crispr的基因组修饰和调控 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20150044772A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| SG11201609211VA (en) | 2014-03-05 | 2016-12-29 | Nat Univ Corp Univ Kobe | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| JP2017518083A (ja) | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 |
| JP2017518082A (ja) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用 |
| CN104450785A (zh) | 2014-12-08 | 2015-03-25 | 复旦大学 | 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒 |
-
2016
- 2016-06-16 EP EP21177979.8A patent/EP3929286A1/en active Pending
- 2016-06-16 DK DK16733813.6T patent/DK3310909T3/da active
- 2016-06-16 KR KR1020187001436A patent/KR102637402B1/ko active Active
- 2016-06-16 US US15/580,675 patent/US11473082B2/en active Active
- 2016-06-16 AU AU2016278226A patent/AU2016278226B2/en active Active
- 2016-06-16 CA CA2989827A patent/CA2989827C/en active Active
- 2016-06-16 ES ES16733813T patent/ES2886599T3/es active Active
- 2016-06-16 WO PCT/US2016/037922 patent/WO2016205554A1/en not_active Ceased
- 2016-06-16 PT PT167338136T patent/PT3310909T/pt unknown
- 2016-06-16 EP EP16733813.6A patent/EP3310909B1/en active Active
- 2016-06-16 CN CN201680047154.3A patent/CN108026519A/zh active Pending
- 2016-06-16 JP JP2018517674A patent/JP2018521689A/ja not_active Ceased
-
2021
- 2021-05-10 JP JP2021079698A patent/JP7170090B2/ja active Active
- 2021-08-31 JP JP2021141109A patent/JP2021182942A/ja not_active Withdrawn
- 2021-10-18 AU AU2021250992A patent/AU2021250992B2/en active Active
-
2022
- 2022-08-25 US US17/822,240 patent/US20230257737A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021112211A5 (enExample) | ||
| GB2556276A (en) | Engineered crispr-CAS9 compositions and methods of use | |
| CY1121894T1 (el) | Θεραπεια hbv | |
| BR112022007481A2 (pt) | Lipídios ionizáveis e composições de nanopartículas dos mesmos | |
| JP2019517268A5 (enExample) | ||
| EA202091673A1 (ru) | Способ амплификации нуклеиновых кислот | |
| WO2007047859A3 (en) | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity | |
| UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
| WO2017053431A3 (en) | Allele selective gene editing and uses thereof | |
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
| JP2018518163A5 (enExample) | ||
| BR0314138A (pt) | composição, e, método | |
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| EP1385370A4 (en) | ANTIMICROBIAL POLYPEPTIDES AND THEIR USE | |
| CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| JP2012505657A5 (enExample) | ||
| CN109963944A (zh) | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA | |
| MX2019015143A (es) | Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso. | |
| JP2019537445A5 (enExample) | ||
| WO2019117660A3 (ko) | Crispr 시스템 기능 향상 방법 및 그의 이용 | |
| ZA202213092B (en) | Codon-optimized nucleic acid that encodes smn1 protein, and use thereof | |
| Lizarraga et al. | Toward incorporating epigenetics into regulation of gene expression in the parasite Trichomonas vaginalis | |
| CN118064467A8 (zh) | 两个或多个靶点嵌合抗原受体基因工程载体及其应用 | |
| US20180187187A1 (en) | Self-assembling molecular nanosystem for targeted dna and gene delivery |